Cross-tissue multiomics reveals that Akkermansia muciniphila counteracts metabolic syndrome by reprograming gut microbiota, oleoylethanolamide and the gut-hypothalamus axis

Abstract

High fructose diet is a major risk factor for metabolic syndrome (MetS). The gut bacterium Akkermansia muciniphila (A. muciniphila) has been shown to improve fructose-induced MetS, but the underlying mechanism remains unclear. Here, we investigated how A. muciniphila modulates fructose-induced MetS using multitissue, multiomics studies encompassing gut microbiota, plasma and gut metabolome, and hypothalamus single cell RNA-sequencing. A. muciniphila colonization enriched beneficial gut bacteria, increased metabolites including bile acids, endocannabinoids, and vitamins, and activated genes related to oxytocin and vasopressin signaling in hypothalamic neurons. Multiomics network analysis prioritized the metabolite oleoylethanolamide (OEA), an endocannabinoid analogue, as a potential regulator of gut-hypothalamic interaction conferred by A. muciniphila, its associated beneficial bacteria, and bile acid remodeling. Oral administration of OEA to fructose-fed mice recapitulated A. muciniphila effects, including counteracting body weight gain, enhancing thermogenesis, and ameliorating glucose intolerance. Concomitantly, OEA supplementation stimulated expression of its receptors and tight junction genes in the intestine, as well as neuronal activation marker c-Fos and oxytocin and vasopressin signaling genes in the hypothalamus. These findings underscore the regulatory role of A. muciniphila in gut microbiota homeostasis and metabolomic reprogramming, and pinpoint OEA as a key mediator of its action on the gut-hypothalamus axis in alleviating fructose-induced MetS.